LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Open

Branche Gesundheitswesen

75.56 0.17

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

75.02

Max

76.5

Schlüsselkennzahlen
By Trading Economics
Einkommen	-973K -16M
Verkäufe	17M 161M
EPS	-0.16
Gewinnspanne	-10.05
Angestellte	610
EBITDA	-6.8M -28M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+27.93 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	31. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-335M 7.1B
Vorheriger Eröffnungskurs	75.39
Vorheriger Schlusskurs	75.56

Nachrichtenstimmung

By Acuity

75%

25%

321 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

73 / 75.85 Unterstützung & Widerstand

Intra-Cellular Therapies Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2024, 01:45 UTC

Ergebnisse

Preview -- Barron's

13. Sept. 2024, 20:03 UTC

Top News

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15. Sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15. Sept. 2024, 16:52 UTC

Top News

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15. Sept. 2024, 09:30 UTC

Top News

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14. Sept. 2024, 14:09 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14. Sept. 2024, 13:25 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ -2-

14. Sept. 2024, 00:01 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13. Sept. 2024, 21:14 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13. Sept. 2024, 21:06 UTC

Top News

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13. Sept. 2024, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13. Sept. 2024, 20:41 UTC

Top News

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13. Sept. 2024, 20:31 UTC

Ergebnisse

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13. Sept. 2024, 20:13 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13. Sept. 2024, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13. Sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13. Sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13. Sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Peer-Vergleich

Kursveränderung

Intra-Cellular Therapies Inc Prognose

Kursziel

By TipRanks

27.93% Vorteil

12-Monats-Prognose

Durchschnitt 96.43 USD 27.93%

Hoch 130 USD

Tief 74 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Intra-Cellular Therapies Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

Buy

Halten

Sell

Basierend auf 15 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Intra-Cellular Therapies Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

73 / 75.85Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Stimmung

By Acuity

321 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.